



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-TSLP Reference Antibody (tezepelumab)	Lot.No.:	P218651
Target:	TSLP	Catalog:	CHB216
Target Accession:	Q969D9	Concentration :	1 mg/mL
Clonality:	Monoclonal	Isotype:	Human IgG2
Reactivity:	Human / Cynomolgus	Molecular Weight (kDa) :	150 kDa
Application:	FCM, Block, In Vivo, ELISA	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

Purity: SDS-PAGE

Purity: SEC-HPLC




Anti- Human TSLP (Tezepelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti- Human TSLP (Tezepelumab) is 98.64%, determined by SEC-HPLC.

Bioactivity: ELISA



Immobilized human TSLP (His Tag, 2µg/mL) can bind to Anti- Human TSLP (Tezepelumab) with an EC50 of 0.0518 ug/mL.


Function: Blocking



The FACS-based blocking activity of the anti- human TSLP (Tezepelumab) was evaluated using TSLPR/IL7R-expressing CHO-K1 cells, with an IC of approximately 0.0802 µg/mL.

The products are for research use only. Not for use in diagnostic procedures.

Research in vivo



Anti- Human TSLP (Tezepelumab) reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.

The products are for research use only. Not for use in diagnostic procedures.